Evidence map›Paper›PMID 31792874›Full record

ArticlePathology oncology research : POR2020

Is it Necessary to Perform Sentinel Lymph Node Biopsy in Thin Melanoma? A Retrospective Single Center Analysis.

A Kocsis, L Karsko, Zs Kurgyis, Zs Besenyi, L Pavics, E Dosa-Racz, E Kis, E Baltas, H Ocsai, E Varga and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Histological regression in melanoma: impact on sentinel lymph node status and survival.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
  6. Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma.Current treatment options in oncology · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

A KocsisDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
L KarskoDepartment of Nuclear Medicine, University of Szeged, Szeged, Hungary.
Zs KurgyisDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Zs BesenyiDepartment of Nuclear Medicine, University of Szeged, Szeged, Hungary.
L PavicsDepartment of Nuclear Medicine, University of Szeged, Szeged, Hungary.
E Dosa-RaczDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
E KisDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
E BaltasDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
H OcsaiDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
E VargaDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
B BendeDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
A VargaDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
G MohosDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
I KoromDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
J VargaDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
L KemenyDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
I B NemethDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary. nemethistvanbalazs@gmail.com.ORCID http://orcid.org/0000-0003-0161-4277
J OlahDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
University of Szeged · HU

Funding

Bolyai Scholarship 2015-18GINOP 2.3.2-15-2016-00020NKFI K-125509
6 · The paper itself

Abstract

Sentinel lymph node biopsy (SLNB) is a standard procedure for regional lymph node staging and still has the most important prognostic value for the outcome of patients with thin melanoma. In addition to ulceration, SLNB had to be considered even for a single mitotic figure in thin (<1 mm) melanoma according to AJCC7th guideline, therefore, a retrospective review was conducted involving 403 pT1 melanoma patients. Among them, 152 patients suffered from pT1b ulcerated or mitotic rate ≥ 1/ mm

Indexed as

AdultAgedCutaneous Malignant MelanomaFemaleHumansLymphatic MetastasisMaleMelanomaMiddle AgedMitotic IndexNeoplasm StagingRetrospective StudiesSentinel Lymph Node BiopsySkin NeoplasmsYoung AdultMelanomaMitotic rateRegressionSentinel lymph node biopsyStage

Identifiers

PMID31792874
PMCPMC7297827
OpenAlexW2993946307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.